Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder - Business Wire

Alzamend Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depression, and Post-Traumatic Stress Disorder

ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers diseas… [+9581 chars]

full article...